In a recent sub-analysis, lenvatinib was shown to improve both progression-free and overall survival in older patients with radioiodine-refractory thyroid cancer.
Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.
Tumor growth rate analysis may be a valuable efficacy parameter to consider in patients with sorafenib-treated, radioiodine-refractory differentiated thyroid cancer.
The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.
Researchers have uncovered two mutations in thyroid tumors that make the tumor either very sensitive to treatment with everolimus, or confers resistance.
My task: teach the residents about oncology. I attempted to impart my newly found knowledge about hematology and oncology to this group of wonderful (even more neophyte than myself), physicians.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.